IRD Opus Genetics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1228627 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.9%
TTM net income YoY-100.4%
TTM EPS YoY20.4%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-777.7%
Net margin-1,726.7%
FCF margin—
EBITDA margin-776.9%
Returns
ROE-615.6%
ROA-208.0%
ROIC (approx.)—
Asset turnover0.12x
Leverage & solvency
Liabilities / assets59.7%
Debt / equity0.93x
Current ratio9.65x
Interest coverage-217.47x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-134.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $14.20M | $10.99M |
| R&D expense | $30.81M | $26.85M |
| SG&A expense | $21.98M | $18.21M |
| Operating income | -$38.60M | -$62.07M |
| Interest expense | $129,000 | $0 |
| Pretax income | -$49.59M | -$57.53M |
| Income tax | $0 | $0 |
| Net income | -$49.59M | -$57.53M |
| EBITDA | -$38.55M | -$62.06M |
| EPS (basic) | -0.80 | -2.15 |
| EPS (diluted) | -0.80 | -2.15 |
| Weighted avg. shares (diluted) | 62.22M | 26.72M |
| Balance sheet | ||
| Cash & equivalents | $45.09M | $30.32M |
| Short-term investments | $0 | $2,000 |
| Receivables | $2.00M | $3.56M |
| Current assets | $50.04M | $36.61M |
| PP&E, net | $199,000 | $252,000 |
| Total assets | $50.24M | $36.86M |
| Current liabilities | $7.78M | $11.29M |
| Long-term debt | $1.13M | $0 |
| Total debt | $1.13M | $0 |
| Total liabilities | $34.90M | $11.29M |
| Shareholders' equity | $15.35M | $6.72M |
| Net debt | -$43.96M | -$30.32M |
| Shares outstanding | 69.89M | 31.57M |
| Cash flow statement | ||
| Operating cash flow | -$35.25M | -$25.58M |
| Investing cash flow | $0 | $1.21M |
| Financing cash flow | $50.02M | $4.19M |
| Depreciation & amortization | $53,000 | $10,000 |
| Stock-based compensation | $3.40M | $3.36M |
Free plan shows the latest 2 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.